{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:05:29Z","timestamp":1794110729628,"version":"4.8.0"},"reference-count":237,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clim.2024.110200","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T16:37:35Z","timestamp":1712248655000},"page":"110200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["New and emerging therapies for systemic lupus erythematosus"],"prefix":"10.1016","volume":"263","author":[{"given":"Eleni","family":"Papachristodoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios C.","family":"Kyttaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0005","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/psp4.12888","article-title":"Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: analysis of pooled patient-level placebo (standard-of-care) data to enable model-informed drug development","volume":"12","author":"Goteti","year":"2023","journal-title":"CPT Pharmacometr. Syst. Pharmacol."},{"issue":"9","key":"10.1016\/j.clim.2024.110200_bb0010","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0015","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215650","article-title":"How to use the lupus low disease activity state (LLDAS) in clinical trials","volume":"80","author":"Parodis","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archdermatol.2010.435","article-title":"Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus","volume":"147","author":"Klein","year":"2011","journal-title":"Arch. Dermatol."},{"issue":"8","key":"10.1016\/j.clim.2024.110200_bb0030","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/rheumatology\/key422","article-title":"Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus","volume":"58","author":"Mahmoud","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0035","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of Belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10289","key":"10.1016\/j.clim.2024.110200_bb0040","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","article-title":"Treatment of lupus nephritis: consensus, evidence and perspectives","volume":"19","author":"Mok","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb0050","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40265-022-01715-1","article-title":"Lupus nephritis: improving treatment options","volume":"82","author":"Kostopoulou","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-022-02756-3","article-title":"\u2018Not at target\u2019: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study","volume":"24","author":"Kandane-Rathnayake","year":"2022","journal-title":"Arthritis Res. Ther."},{"issue":"23","key":"10.1016\/j.clim.2024.110200_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20236021","article-title":"Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"Ma","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clim.2024.110200_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2016.07.002","article-title":"DNA-reactive B cells in lupus","volume":"43","author":"Suurmond","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0070","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: what have we learnt?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: areview in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0080","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of Belimumab in patients of black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0090","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of Belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study","volume":"17","author":"Furie","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb0100","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110200_bb0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J. Autoimmun."},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0110","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus\u202f: arandomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0120","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40744-022-00454-9","article-title":"Real-world effectiveness of belimumab in systemic lupus erythematosus: asystematic literature review","volume":"9","author":"Huang","year":"2022","journal-title":"Rheumatol. Ther."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0125","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000529675","article-title":"Efficacy and safety of belimumab in lupus nephritis patients: areal-world observational study in China","volume":"9","author":"Tan","year":"2023","journal-title":"Kidney Dis (Basel)."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0135","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.clim.2024.110200_bb0140","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.clim.2024.110200_bb0145","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110200_bb0150","first-page":"1331","article-title":"Profile of atacicept and its potential in the treatment of systemic lupus erythematosus","volume":"9","author":"Cogollo","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"26","key":"10.1016\/j.clim.2024.110200_bb0155","doi-asserted-by":"crossref","first-page":"16330","DOI":"10.1074\/jbc.M115.661405","article-title":"Stoichiometry of heteromeric BAFF and APRIL cytokines dictates their receptor binding and signaling properties","volume":"290","author":"Schuepbach-Mallepell","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0160","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0165","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of Atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm. Phase IIb Study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0170","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0175","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/art.39809","article-title":"Post hoc analysis of the phase II\/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL","volume":"69","author":"Gordon","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb0180","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/rheumatology\/keaa029","article-title":"Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study","volume":"59","author":"Morand","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0185","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1093\/rheumatology\/keab115","article-title":"Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus","volume":"60","author":"Wallace","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0190","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/rheumatology\/keac523","article-title":"Atacicept-it\u2019s not over until the wolf-lady sings (or maybe howls)","volume":"62","author":"Isenberg","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0195","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 9","key":"10.1016\/j.clim.2024.110200_bb0200","article-title":"Telitacicept, a human recombinant fusion protein targeting b lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL), in systemic lupus erythematosus (SLE): results of a phase 3 study","volume":"74","author":"Wu","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0205","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/09612033221141253","article-title":"The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study","volume":"32","author":"Chen","year":"2023","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb0210","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/1756-185X.14613","article-title":"Safety, efficacy and pharmacokinetics of low-dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus","volume":"26","author":"Guan","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0215","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1620\/tjem.2022.J074","article-title":"Telitacicept for recalcitrant cutaneous manifestations of systemic lupus erythematosus: acase report and review of the literature","volume":"258","author":"Ma","year":"2022","journal-title":"Tohoku J. Exp. Med."},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb0220","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl. 9","key":"10.1016\/j.clim.2024.110200_bb0225","article-title":"ALPN-303, an enhanced, potent dual BAFF\/APRIL antagonist engineered by directed evolution for the treatment of systemic lupus erythematosus (SLE) and other B cell-related diseases","volume":"73","author":"Dillon","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"Supplement 1","key":"10.1016\/j.clim.2024.110200_bb0230","doi-asserted-by":"crossref","first-page":"8401","DOI":"10.1182\/blood-2022-155908","article-title":"A randomized, placebo-controlled, phase 1 study in healthy adult volunteers of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN303, a potent dual BAFF\/APRIL antagonist for the treatment of autoimmune cytopenias","volume":"140","author":"Dillon","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clim.2024.110200_bb0235","article-title":"Phase 2 safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFFR mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE) of moderate-to-severe activity","volume":"75","author":"NIS","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2024.110200_bb0240","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fmed.2020.00316","article-title":"B cell therapy in systemic lupus erythematosus: from rationale to clinical practice","volume":"7","author":"Parodis","year":"2020","journal-title":"Front. Med. (Lausanne)."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0245","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0250","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.clim.2024.110200_bb0255","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0260","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.clim.2024.110200_bb0265","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0270","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/rheumatology\/keu475","article-title":"Ofatumumab: a novel treatment for severe systemic lupus erythematosus","volume":"54","author":"Thornton","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0275","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/ckj\/sfw022","article-title":"Ofatumumab treatment in lupus nephritis patients","volume":"9","author":"Haarhaus","year":"2016","journal-title":"Clin. Kidney J."},{"issue":"14","key":"10.1016\/j.clim.2024.110200_bb0280","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1177\/0961203319881500","article-title":"Successful treatment of systemic lupus erythematosus-related refractory autoimmune hemolytic anemia with ofatumumab","volume":"28","author":"Poulet","year":"2019","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb0285","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0290","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"Supplement 1","key":"10.1016\/j.clim.2024.110200_bb0295","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2021-146440","article-title":"The type II Glycoengineered humanized anti-CD20 monoclonal antibody MIL62 combined with lenalidomide in Chinese patients with relapsed\/refractory follicular lymphoma and marginal zone lymphoma: results of a multicenter, single-arm, phase 1b\/2 trial","volume":"138","author":"Shi","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clim.2024.110200_bb0300","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.clinthera.2016.03.028","article-title":"Safety, tolerability, pharmacokinetic and Pharmacodynamic properties of SBI-087, a CD20-directed B-cell depleting agent: phase 1 dose escalating studies in patients with either mild rheumatoid arthritis or systemic lupus","volume":"38","author":"Cohen","year":"2016","journal-title":"Clin. Ther."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0305","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","article-title":"Mosunetuzumab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0310","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0315","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of Epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind. Placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.clim.2024.110200_bb0320","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.40425","article-title":"Efficacy of epratuzumab, an anti-CD22 monoclonal IgG antibody, in systemic lupus erythematosus patients with associated Sj\u00f6gren\u2019s syndrome","volume":"70","author":"Gottenberg","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb0325","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.4049\/jimmunol.1003412","article-title":"Antibody-mediated coengagement of Fc\u03b3RIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus","volume":"186","author":"Horton","year":"2011","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2024.110200_bb0330","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.40086","article-title":"The biomarkers of lupus disease study: a bold approach may mitigate interference of background Immunosuppressants in clinical trials","volume":"69","author":"Merrill","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2024.110200_bb0335","first-page":"A73","article-title":"98\u00a0results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb\u00ae5871, in systemic lupus erythematosus (SLE)","volume":"6","author":"Merrill","year":"2019","journal-title":"Lupus Sci. Med."},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0340","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14712598.2022.2026921","article-title":"Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from lupus","volume":"22","author":"Radic","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.clim.2024.110200_bb0345","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb0350","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2024.110200_bb0355","article-title":"Novel BCMA-CD19 compound CAR-T (cCAR) targets B cells and plasma cells achieving immune reset and eliminates all autoantibodies in systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients resulting in long-term, medication-free remission","volume":"75","author":"Yuan","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0360","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/acr2.11614","article-title":"Journal Club: anti-CD19 chimeric antigen receptor T cell therapy for refractory systemic lupus erythematosus","volume":"5","author":"Boulougoura","year":"2023","journal-title":"ACR Open Rheumatol."},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0365","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0370","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/ard-2023-224152","article-title":"Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosus","volume":"82","author":"Alexander","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0375","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb0380","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb0385","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/rheumatology\/kez623","article-title":"A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE","volume":"59","author":"van Dam","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0390","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5583","article-title":"Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: a clinical case report","volume":"10","author":"Crawford","year":"2022","journal-title":"Clin. Case Reports"},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0395","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0961203319896018","article-title":"Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience","volume":"29","author":"Segarra","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.clim.2024.110200_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.756941","article-title":"Clinical experience of proteasome inhibitor Bortezomib regarding efficacy and safety in severe systemic lupus erythematosus: a nationwide study","volume":"12","author":"Walhelm","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2024.110200_bb0405","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0961203316686703","article-title":"The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis","volume":"26","author":"Zhang","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.clim.2024.110200_bb0410","doi-asserted-by":"crossref","DOI":"10.1177\/1721727X221105152","article-title":"Efficacy of bortezomib in reduction of systemic lupus erythematosus disease activity index score: a meta-analysis","volume":"20","author":"He","year":"2022","journal-title":"Eur. J. Inflamm."},{"issue":"6","key":"10.1016\/j.clim.2024.110200_bb0415","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/14397595.2018.1432331","article-title":"Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus","volume":"28","author":"Ishii","year":"2018","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0420","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/1744666X.2023.2145281","article-title":"B cell depletion and inhibition in systemic lupus erythematosus","volume":"19","author":"Krustev","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2024.110200_bb0425","first-page":"595","article-title":"POS0695 KZR-616, a selective immunoproteasome inhibitor for the treatment of systemic lupus erythematosus: results from the completed dose escalation phase 1b portion of the mission study","volume":"80","author":"Furie","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2024.110200_bb0430","first-page":"891","article-title":"POS1128\u00a0zetomipzomib (KZR-616) treatment results in clinically meaningful renal responses in patients with lupus nephritis","volume":"82","author":"Saxena","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110200_bb0435","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/ITT.S240874","article-title":"Bruton\u2019s tyrosine kinase inhibitors: anew therapeutic target for the treatment of SLE?","volume":"9","author":"Lorenzo-Vizcaya","year":"2020","journal-title":"Immunotargets Ther."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb0440","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the Bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind. Placebo-controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0445","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/acr2.11511","article-title":"Efficacy and safety of the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind. Placebo-controlled dose-ranging trial","volume":"5","author":"Wallace","year":"2023","journal-title":"ACR Open Rheumatol."},{"issue":"Suppl. 9","key":"10.1016\/j.clim.2024.110200_bb0450","article-title":"Efficacy and safety of ABBV-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg) and upadacitinib monotherapy for the treatment of systemic lupus erythematosus: a phase 2, double-blind, placebo-controlled trial [abstract]","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2024.110200_bb0455","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2022-eular.5086a","article-title":"LB0005 orelabrutinib, an irreversible inhibitor of Bruton\u2019s tyrosine kinase (BTK), for the treatment of systemic lupus erythematosus (SLE): results of a randomized, double-blind, placebo-controlled, phase Ib\/IIa dose-finding study","volume":"81","author":"Li","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0460","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000581","article-title":"Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study","volume":"9","author":"Furie","year":"2022","journal-title":"Lupus Sci. Med."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb0465","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/annrheumdis-2017-212916","article-title":"Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus","volume":"77","author":"Schafer","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0470","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 9","key":"10.1016\/j.clim.2024.110200_bb0475","article-title":"KPG-818, a novel cereblon (CRBN) modulator, in patients with SLE: results of a phase Ib multiple ascending dose study [abstract]","volume":"74","author":"Gupta","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0480","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.4049\/jimmunol.178.3.1960","article-title":"Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus","volume":"178","author":"Kyttaris","year":"2007","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0485","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031263","article-title":"Calcineurin and systemic lupus erythematosus: the rationale for using calcineurin inhibitors in the treatment of lupus nephritis","volume":"22","author":"Rafael-Vidal","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.clim.2024.110200_bb0490","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/s10165-009-0218-5","article-title":"Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study","volume":"19","author":"Miyasaka","year":"2009","journal-title":"Mod. Rheumatol."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0495","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/0961203313502864","article-title":"Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study","volume":"22","author":"Mok","year":"2013","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0500","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.ajkd.2010.08.036","article-title":"Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial","volume":"57","author":"Chen","year":"2011","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0505","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.4492","article-title":"Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis: arandomized clinical trial","volume":"5","author":"Zheng","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0510","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/0961203317739131","article-title":"Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial","volume":"27","author":"Kamanamool","year":"2018","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.clim.2024.110200_bb0515","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","article-title":"Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis","volume":"79","author":"Mok","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb0520","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1681\/ASN.2007121272","article-title":"Successful treatment of class V+IV lupus nephritis with multitarget therapy","volume":"19","author":"Bao","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0525","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0530","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1440-1797.2012.01574.x","article-title":"Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome","volume":"17","author":"Yap","year":"2012","journal-title":"Nephrology (Carlton)"},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0535","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/rheumatology\/ken335","article-title":"Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis","volume":"47","author":"Szeto","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.clim.2024.110200_bb0540","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/0961203312442259","article-title":"Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial","volume":"21","author":"Chen","year":"2012","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0545","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.191008","article-title":"Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis: 5-year interim postmarketing surveillance study in Japan (TRUST)","volume":"48","author":"Takeuchi","year":"2021","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.clim.2024.110200_bb0550","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/mr\/roac094","article-title":"Tacrolimus use and renal function in pregnancy with lupus nephritis: analysis of post-marketing surveillance data in Japan","volume":"33","author":"Suzuki","year":"2023","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0555","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0560","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term Voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb0565","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/acr.25007","article-title":"Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis","volume":"75","author":"Arriens","year":"2023","journal-title":"Arthritis Care Res."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0570","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrrheum.2015.172","article-title":"Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases","volume":"12","author":"Perl","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2024.110200_bb0575","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.trsl.2022.03.004","article-title":"Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis","volume":"245","author":"Caza","year":"2022","journal-title":"Transl. Res."},{"issue":"5","key":"10.1016\/j.clim.2024.110200_bb0580","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.semarthrit.2020.07.006","article-title":"Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"50","author":"Ji","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110200_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108781","article-title":"Improvement of renal and non-renal SLE outcome measures on sirolimus therapy - a 21-year follow-up study of 73 patients","volume":"229","author":"Piranavan","year":"2021","journal-title":"Clin. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2024.110200_bb0590","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/art.34502","article-title":"N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Lai","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0595","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13063-023-07083-9","article-title":"Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study","volume":"24","author":"Abbasifard","year":"2023","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0600","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40880-017-0184-9","article-title":"Metformin targets multiple signaling pathways in cancer","volume":"36","author":"Lei","year":"2017","journal-title":"Chin. J. Cancer"},{"issue":"274","key":"10.1016\/j.clim.2024.110200_bb0605","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0835","article-title":"Normalization of CD4+ T cell metabolism reverses lupus","volume":"7","author":"Yin","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0610","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1016\/S2665-9913(20)30004-7","article-title":"Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Sun","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0615","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1002\/art.39296","article-title":"Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin","volume":"67","author":"Wang","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0620","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08916930601095148","article-title":"Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration","volume":"40","author":"Harada","year":"2007","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0630","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.clim.2015.04.004","article-title":"Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL\/lpr mice","volume":"158","author":"Edwards","year":"2015","journal-title":"Clin. Immunol."},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0635","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/0961203319877242","article-title":"T cell-specific STAT3 deficiency abrogates lupus nephritis","volume":"28","author":"Yoshida","year":"2019","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0640","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb0645","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","article-title":"Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre","volume":"78","author":"You","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"10143","key":"10.1016\/j.clim.2024.110200_bb0650","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"issue":"10381","key":"10.1016\/j.clim.2024.110200_bb0655","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"issue":"10381","key":"10.1016\/j.clim.2024.110200_bb0660","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0665","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: aphase II, randomized, double-blind. Placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0670","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001490","article-title":"Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy","volume":"6","author":"Baker","year":"2020","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.clim.2024.110200_bb0675","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","article-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"61","author":"Werth","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"13","key":"10.1016\/j.clim.2024.110200_bb0680","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.clim.2024.110200_bb0685","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/bjd.16337","article-title":"Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus","volume":"178","author":"Presto","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0690","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind. Placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol."},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0695","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.clim.2024.110200_bb0700","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1172\/JCI42856","article-title":"Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice","volume":"120","author":"Biswas","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.clim.2024.110200_bb0705","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/0961203312436862","article-title":"Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB\/W F1 female mice","volume":"21","author":"Stirzaker","year":"2012","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0710","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/annrheumdis-2016-209850","article-title":"Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE","volume":"76","author":"Rozo","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.retram.2022.103343","article-title":"Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease","volume":"70","author":"Ali","year":"2022","journal-title":"Curr Res Transl Med."},{"key":"10.1016\/j.clim.2024.110200_bb0720","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pupt.2017.08.002","article-title":"Effects of fasudil on pulmonary hypertension in clinical practice","volume":"46","author":"Zhang","year":"2017","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"20","key":"10.1016\/j.clim.2024.110200_bb0725","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0730","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/art.39470","article-title":"Abatacept inhibition of T cell priming in mice by induction of a unique transcriptional profile that reduces their ability to activate antigen-presenting cells","volume":"68","author":"Patakas","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb0735","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0740","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0745","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study","volume":"66","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0750","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jcph.791","article-title":"Pharmacokinetic, pharmacodynamic, and safety profile of a novel anti-CD28 domain antibody antagonist in healthy subjects","volume":"57","author":"Shi","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.clim.2024.110200_bb0755","first-page":"70","article-title":"An anti-CD28 domain antibody, lulizumab, in systemic lupus erythematosus: results of a phase II study","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0760","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/PL00000776","article-title":"The CD40\/CD154 receptor\/ligand dyad","volume":"58","author":"Sch\u00f6nbeck","year":"2001","journal-title":"Cell. Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb0765","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/0961203315574558","article-title":"First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus","volume":"24","author":"Tocoian","year":"2015","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0770","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0775","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/art.42557","article-title":"Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: arandomized, double-blind, placebo-controlled. Phase II trial","volume":"75","author":"Jayne","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0780","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41573-020-0081-9","article-title":"Targeting co-stimulatory molecules in autoimmune disease","volume":"19","author":"Edner","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0785","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4049\/jimmunol.1700418","article-title":"IL-23 limits the production of IL-2 and promotes autoimmunity in lupus","volume":"199","author":"Dai","year":"2017","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb0790","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1002\/art.20519","article-title":"Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus","volume":"50","author":"Hutloff","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0795","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000146","article-title":"Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus","volume":"3","author":"Sullivan","year":"2016","journal-title":"Lupus Sci. Med."},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb0800","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/art.40479","article-title":"Brief report: arandomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis","volume":"70","author":"Cheng","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2024.110200_bb0805","first-page":"70","article-title":"Development and first-in-human characterization of an ICOSL and BAFF bispecific inhibitor AMG 570 for SLE treatment","author":"Cheng LE","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb0810","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/cts.12983","article-title":"First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28\/ICOS antagonist, in healthy adult subjects","volume":"14","author":"Yang","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.clim.2024.110200_bb0815","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.3389\/fimmu.2018.02994","article-title":"CD6, a rheostat-type signalosome that tunes T cell activation","volume":"9","author":"Gon\u00e7alves","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0820","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147334","article-title":"The CD6\/ALCAM pathway promotes lupus nephritis via T cell-mediated responses","volume":"132","author":"Chalmers","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2024.110200_bb0825","article-title":"Kopyt n, Connelly S, Sun E, et al. clinical safety and efficacy results from EQUALISE type B: aphase 1b open-label clinical study of Itolizumab, a novel anti-CD6 therapy, in subjects with active proliferative lupus nephritis","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2024.110200_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102870","article-title":"Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies","volume":"132","author":"Li","year":"2022","journal-title":"J. Autoimmun."},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0835","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"22","key":"10.1016\/j.clim.2024.110200_bb0840","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110200_bb0845","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3389\/fimmu.2018.00786","article-title":"Targeting regulatory T cells to treat patients with systemic lupus erythematosus","volume":"9","author":"Mizui","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2024.110200_bb0850","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0855","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0860","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0865","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2024.110200_bb0870","first-page":"A96","article-title":"PO.6.127\u00a0Efavaleukin alfa, a novel IL-2 mutein, selectively expands regulatory t cells in patients with SLE: final results of a phase 1b multiple ascending dose study","volume":"9","author":"Tchao","year":"2022","journal-title":"Lupus Sci. Med."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0875","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1535370218824547","article-title":"IL-12 and IL-23\/Th17 axis in systemic lupus erythematosus","volume":"244","author":"Larosa","year":"2019","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"14","key":"10.1016\/j.clim.2024.110200_bb0880","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1177\/0961203320952841","article-title":"Interleukin 23 is elevated in the serum of patients with SLE","volume":"29","author":"Vukelic","year":"2020","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2008.04.004","article-title":"T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis","volume":"128","author":"Cohen","year":"2008","journal-title":"Clin. Immunol."},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0890","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys","volume":"181","author":"Crispin","year":"2008","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2024.110200_bb0895","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.4049\/jimmunol.0900385","article-title":"The role of IL-23\/IL-17 axis in lupus nephritis","volume":"183","author":"Zhang","year":"2009","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2024.110200_bb0900","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.4049\/jimmunol.0903595","article-title":"Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL\/6-lpr\/lpr mice","volume":"184","author":"Kyttaris","year":"2010","journal-title":"J. Immunol."},{"issue":"10155","key":"10.1016\/j.clim.2024.110200_bb0905","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0910","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0915","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/labinvest.3700468","article-title":"IL-10 regulation of lupus in the NZM2410 murine model","volume":"86","author":"Blenman","year":"2006","journal-title":"Lab. Investig."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0920","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150515","article-title":"IL-10 production is critical for sustaining the expansion of CD5+ B and NKT cells and restraining autoantibody production in congenic lupus-prone mice","volume":"11","author":"Baglaenko","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clim.2024.110200_bb0925","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970906","article-title":"IL-10 revisited in systemic lupus erythematosus","volume":"13","author":"Biswas","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.clim.2024.110200_bb0930","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2","article-title":"Clinical and biologic effects of anti\u2013interleukin-10 monoclonal antibody administration in systemic lupus erythematosus","volume":"43","author":"Llorente","year":"2000","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb0935","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1089\/jir.2018.0169","article-title":"Changes of serum IL-6, IL-17, and complements in systemic lupus erythematosus patients","volume":"39","author":"Tang","year":"2019","journal-title":"J. Interf. Cytokine Res."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0940","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clim.2008.08.018","article-title":"The effects of IL-6 on CD4 T cell responses","volume":"130","author":"Dienz","year":"2009","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0945","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028415","article-title":"Interleukin-6 family cytokines","volume":"10","author":"Rose-John","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb0950","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1177\/0961203315588971","article-title":"Association of the interleukin-6 polymorphisms with systemic lupus erythematosus: a meta-analysis","volume":"24","author":"Cui","year":"2015","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0955","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3899\/jrheum.090194","article-title":"Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus","volume":"37","author":"Cash","year":"2010","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb0960","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb0965","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","article-title":"Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial","volume":"76","author":"Wallace","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.clim.2024.110200_bb0970","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/art.39722","article-title":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with Sirukumab (CNTO 136) in patients with active lupus nephritis","volume":"68","author":"Rovin","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2024.110200_bb0975","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0980","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci. Med."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0985","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/art.34632","article-title":"Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study","volume":"64","author":"McBride","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb0990","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb0995","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb1000","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12969-019-0361-2","article-title":"Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon","volume":"17","author":"Patwardhan","year":"2019","journal-title":"Pediatr. Rheumatol. Online J."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb1005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1358\/dot.2023.59.2.3521876","article-title":"Anifrolumab in systemic lupus erythematosus","volume":"59","author":"Loncharich","year":"2023","journal-title":"Drugs Today (Barc.)"},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb1010","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb1015","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb1020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb1025","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/ced.15335","article-title":"Anifrolumab for treatment of refractory cutaneous lupus erythematosus","volume":"47","author":"Blum","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb1030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb1035","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/annrheumdis-2021-221847","article-title":"Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2\/3 trials","volume":"81","author":"Bruce","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb1040","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.41778","article-title":"What does it mean to be a British Isles lupus assessment group-based composite lupus assessment responder? Post hoc analysis of two phase III trials","volume":"73","author":"Furie","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb1045","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00393-020-00928-7","article-title":"Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials","volume":"80","author":"Lee","year":"2021","journal-title":"Z. Rheumatol."},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb1050","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/rheumatology\/keac491","article-title":"Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials","volume":"62","author":"Bruce","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb1055","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb1060","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.41518","article-title":"Modulation of cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus","volume":"73","author":"Casey","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb1065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/annrheumdis-2019-216379","article-title":"IFN-\u03b1 kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study","volume":"79","author":"Houssiau","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb1070","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.37785","article-title":"Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon \u03b1-kinoid","volume":"65","author":"Lauwerys","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb1075","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/rheumatology\/kew262","article-title":"Interferon \u03b1 kinoid induces neutralizing anti-interferon \u03b1 antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon \u03b1 kinoid phase I\/II study","volume":"55","author":"Ducreux","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2024.110200_bb1080","article-title":"IFN-\u03b3, should not be ignored in SLE","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb1085","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/art.39248","article-title":"Blockade of interferon-\u03b3 normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus","volume":"67","author":"Welcher","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb1090","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s11095-014-1492-2","article-title":"Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-\u03b3 IgG1 monoclonal antibody, in patients with systemic lupus erythematosus","volume":"32","author":"Chen","year":"2015","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.clim.2024.110200_bb1095","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/art.40052","article-title":"Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-\u03b3 antibody, in patients with discoid lupus erythematosus","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb1100","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000226","article-title":"Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-\u03b3 monoclonal antibody, in SLE subjects without or with lupus nephritis","volume":"4","author":"Boedigheimer","year":"2017","journal-title":"Lupus Sci. Med."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb1105","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1172\/JCI127101","article-title":"A promising approach to targeting type 1 IFN in systemic lupus erythematosus","volume":"129","author":"Chaichian","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb1110","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.clim.2024.110200_bb1115","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody Litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.clim.2024.110200_bb1120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody Litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb1125","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.40828","article-title":"Safety and tolerability of omalizumab: arandomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus","volume":"71","author":"Hasni","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb1130","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s13063-021-05475-3","article-title":"Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study)","volume":"22","author":"Yan","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.clim.2024.110200_bb1135","article-title":"Efficacy and safety of iguratimod as an add-on therapy for refractory lupus nephritis: a preliminary investigational study","volume":"14","author":"Yan","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.clim.2024.110200_bb1140","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/13543784.2020.1777983","article-title":"Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy","volume":"29","author":"Talotta","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"12","key":"10.1016\/j.clim.2024.110200_bb1145","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1002\/art.24027","article-title":"Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial","volume":"58","author":"Muller","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.clim.2024.110200_bb1150","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1136\/annrheumdis-2012-202460","article-title":"Lupuzor\/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial","volume":"72","author":"Zimmer","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb1155","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000354","article-title":"First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study","volume":"6","author":"Hermann","year":"2019","journal-title":"Lupus Sci. Med."},{"issue":"2","key":"10.1016\/j.clim.2024.110200_bb1160","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar4520","article-title":"Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study","volume":"16","author":"Wang","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"8","key":"10.1016\/j.clim.2024.110200_bb1165","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/art.38674","article-title":"A CD8 T cell\/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus","volume":"66","author":"Wang","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110200_bb1170","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000704","article-title":"Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE","volume":"9","author":"Kamen","year":"2022","journal-title":"Lupus Sci. Med."},{"issue":"8","key":"10.1016\/j.clim.2024.110200_bb1175","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","article-title":"A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis","volume":"76","author":"Deng","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.clim.2024.110200_bb1180","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.clim.2024.110200_bb1185","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624000913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624000913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:44:15Z","timestamp":1715975055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661624000913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":237,"alternative-id":["S1521661624000913"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2024.110200","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and emerging therapies for systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2024.110200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110200"}}